Abstract 1308P
Background
High false positive rates in LDCT screening are an important concern. The study aims to explore the diagnostic performance of different diameter thresholds for various lung nodules to reduce unnecessary follow-up LDCT scans and the waste of medical resources.
Methods
Participants were recruited from the "Guangzhou Lung-Care Project" at the First Affiliated Hospital of Guangzhou Medical University in China between 2017 and 2021. The average transverse diameter of lung nodules was measured by semi-automatic segmentation. Positive outcomes were divided into two groups: outcome 1-lung cancer diagnosis with AAH/AIS, and outcome 2-lung cancer diagnosis without AAH/AIS. We calculated the area under the receiver-operating characteristic curves (AUCs), sensitivity, specificity, positive prediction rate(ppv) and negative prediction rate (NPV) to evaluate the diagnostic performance of lung cancer under each threshold between 5mm to 10mm.
Results
In the first year after LDCT screening, 126 cases of lung cancer (including 13 cases of AAH/AIS) were diagnosed among the participants of 11,705 (5,425 men and 6,280 women; median age 59). Increase the average transverse diameter threshold from 5 to 7mm in all lung nodules (solid, part-solid, non-solid), and gradually increase the AUC in outcome 1 (0.766 to 0.825) and outcome 2 (0.78 to 0.839). From 7 to 10mm, the AUC in outcome 1 (0.825 to 0.764) and outcome 2 (0.839 to 0.778) is gradually reduced. In the outcome 2, when the diameter threshold was increased from 5mm to 8mm, the specificity (60.06% to 90.82%) and ppv (6.57% to 19.02%) increased significantly, the sensitivity was reduced (94.02% to 76.07%). When the diameter threshold was increased from 8mm to 10mm, the sensitivity was significantly reduced (76.07% to 60.68%) and specificity (90.82% to 94.88%) and ppv (19.02% to 25.13%) increased slightly. There is no obvious difference between outcome 1 and outcome 2 in the above indicators.
Conclusions
Our study demonstrates that setting a diameter threshold of 8mm for LDCT screening of lung nodules achieves better overall diagnostic performance, reducing false positives and unnecessary follow-up scans while minimizing medical resource waste.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wenhua Liang.
Funding
The First Affiliated Hospital of Guangzhou Medical University; China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
466P - Integrated analysis of potential prognosis and differential expression between primary and metastatic foci for COL12A1 in breast cancer
Presenter: Lei Tang
Session: Poster session 04
467P - Initial results from the Canarian registry of luminal breast cancer patients treated with first-line CDK 4/6 inhibitors
Presenter: Isaac Ceballos Lenza
Session: Poster session 04
468P - Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study
Presenter: Eda Caliskan Yildirim
Session: Poster session 04
469P - Metastasic breast cancer: Differences in motor activity and sleep patterns by kind of treatment
Presenter: Maria Torrente
Session: Poster session 04
470P - Increased risk of vertebral fractures in healthy bone in metastatic breast cancer patients treated with CDK4/6 inhibitors combined with endocrine therapy
Presenter: Marco Bergamini
Session: Poster session 04
471P - Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
Presenter: Chiara Paratore
Session: Poster session 04
472P - Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
Presenter: Joshua Tobias
Session: Poster session 04
473P - Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
Presenter: Kreina Vega Cano
Session: Poster session 04
474P - ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer
Presenter: Aaron Lin
Session: Poster session 04
475P - Dynamics of TROP2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04